Refine by
Tumor Targeting Services
12 services found
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a target. However, this paradigm is limited by the expression of tumor targets on healthy cells, resulting ...
Manufactured by:Invicro, LLC based inNeedham, MASSACHUSETTS (USA)
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue. Streamlined development, evaluation and clinical translation of ...
Manufactured by:Inovotion Sas based inLa Tronche, FRANCE
Target validation is an essential and critical phase of the drug discovery process. This is a crucial step before starting to develop a treatment based on a targeted protein that has been identified to play a role in the disease. The target protein’s role must be clearly identified before starting to develop a drug candidate against the disease and evaluate if the drug acts on the ...
by:SonALAsense based inBerkeley, CALIFORNIA (USA)
We are committed to providing hope in the face of despair with a unique proprietary non-invasive drug-device combination therapy, ALA Sonodynamic Therapy (SDT), for the treatment of recurrent glioblastoma multiforme (rGBM). ...
by:Oncimmune Holdings PLC based inNottingham, UNITED KINGDOM
Viewing cancer through the immune lens (immuno-oncology) has led to the most promising advancements in cancer treatment in recent history, nonetheless the full potential of the approach is as yet ...
Manufactured by:ITM Isotope Technologies Munich SE based inGarching / Munich, GERMANY
Targeted Radionuclide Therapy (TRT) or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like cancer. Once injected into the patient, the radiopharmaceutical finds its way to the tumor through the bloodstream and binds to the ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
Proteolysis targeting chimera (PROTAC) drugs offer a novel approach to disease treatment by leveraging the body's innate protein degradation pathways. In contrast to traditional small-molecule inhibitors, PROTAC drugs promote the degradation of specific proteins rather than directly inhibiting their function, thus mitigating or eliminating their role in disease progression. ...
Manufactured by:Invicro, LLC based inNeedham, MASSACHUSETTS (USA)
Prostate cancer is the most common type of cancer (aside from skin) in American men with 13 out of every 100 being diagnosed with the disease during their lifetime.1,2Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is expressed in high levels in prostate cancer cells. Due to its location on the cell surface, PSMA is a popular target for imaging to ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
PROTACs represent a novel strategy for protein degradation that has gained prominence recently. Utilizing bifunctional molecules, PROTACs enable the targeted ubiquitination and subsequent degradation of proteins via the UPS. PROTACs can not only offer potential therapeutic applications for a variety of conditions, including cancer, immune dysregulation, viral infections, and neurodegenerative ...
by:MtoZ Biolabs based in, MASSACHUSETTS (USA)
PROTACs represent a novel strategy for protein degradation that has gained prominence recently. Utilizing bifunctional molecules, PROTACs enable the targeted ubiquitination and subsequent degradation of proteins via the UPS. PROTACs can not only offer potential therapeutic applications for a variety of conditions, including cancer, immune dysregulation, viral infections, and neurodegenerative ...